Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

16.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.5K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.4K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.

ESMO open·2025
Same author

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.

ESMO open·2025
Same author

Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years.

Ocular immunology and inflammation·2024
Same author

Preliminary assessment of persistent organic pollutants (POPs) in tissues of Risso's dolphin (Grampus griseus) specimens stranded along the Italian coasts.

Marine pollution bulletin·2022
Same author

Transcriptomic landscape of TIMP3 oncosuppressor activity in thyroid carcinoma.

Cancer cell international·2022
Same author

Corrigendum to "Cast iron street furniture: A historical review" [Endeavour 44 (3) (2020) 100721].

Endeavour·2021
Same journal

Deconvoluting MLL1-dependent pathways in hematopoiesis and leukemogenesis.

Leukemia supplements·2016
Same journal

New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance.

Leukemia supplements·2016
Same journal

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

Leukemia supplements·2016
Same journal

Dissecting reprogramming, differentiation and conversion with network biology.

Leukemia supplements·2016
Same journal

Insights into the pathophysiology and therapy of myeloproliferative neoplasms from mouse models.

Leukemia supplements·2016
Same journal

Myeloid differentiation and the leukemia-initiating cell.

Leukemia supplements·2016
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.7K

Prognostic factors in CLL.

M Ferrarini1, G Cutrona1, A Neri2

  • 1IRCCS Azienda Ospedaliera Universitaria San Martino IST , Genova, Italy.

Leukemia Supplements
|May 14, 2016
PubMed
Summary
This summary is machine-generated.

Prognosis in chronic lymphocytic leukemia (CLL) varies. Unmutated IGHV genes and CD38 expression indicate a poorer outcome in early-stage CLL patients, guiding personalized treatment strategies.

Keywords:
Binet A stageCLLgene expression profilemiRNAprognostic markersscore

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

Related Experiment Videos

Last Updated: Mar 21, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.7K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic lymphocytic leukemia (CLL) exhibits significant clinical heterogeneity, with variable disease progression and treatment needs.
  • Early studies identified distinct CLL cell clones with varying phenotypic and genotypic features.
  • Retrospective analyses linked unmutated IGHV genes, CD38, and ZAP-70 expression to a more severe prognosis in CLL patients.

Purpose of the Study:

  • To prospectively evaluate the predictive value of IGHV gene mutational status, CD38, and ZAP-70 expression in early-stage (Binet A) CLL patients.
  • To compare the prognostic significance of these markers with chromosomal abnormalities and gene/microRNA profiles.
  • To explore the potential pathogenetic roles of these prognostic markers in CLL.

Main Methods:

  • Prospective study design involving Binet A-stage CLL patients.
  • Determination of IGHV gene mutational status, CD38, and ZAP-70 expression at diagnosis.
  • Assessment of chromosomal abnormalities, gene expression, and microRNA profiles.
  • Statistical analysis to evaluate the predictive value of identified markers.

Main Results:

  • Confirmed the significant prognostic value of unmutated IGHV genes, CD38 expression, and ZAP-70 expression in early-stage CLL.
  • Demonstrated that these markers, when assessed prospectively, provide crucial information for predicting disease course.
  • Identified correlations between these markers and other molecular profiles, offering insights into CLL pathogenesis.

Conclusions:

  • Unmutated IGHV genes, CD38, and ZAP-70 expression are key independent prognostic factors in early-stage CLL.
  • These markers aid in stratifying patients for risk-adapted therapeutic strategies.
  • Further research into the pathogenetic mechanisms underlying these markers is warranted to improve CLL management.